Methora 15 Tablet contains Methotrexate 15 mg, a folate antagonist used primarily in the treatment of various malignancies and autoimmune diseases. Methotrexate acts by inhibiting dihydrofolate reductase, an enzyme involved in the synthesis of tetrahydrofolate, thereby interfering with DNA synthesis, repair, and cellular replication. This mechanism makes it effective in rapidly dividing cells, such as cancer cells and activated immune cells. Methora 15 is indicated for conditions including acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, psoriasis, rheumatoid arthritis, and ectopic pregnancy. The dosage and duration of therapy with Methora 15 Tablet should be individualized based on the specific condition, patient response, and tolerance. Due to its potent effects and potential toxicity, therapy requires close monitoring of blood counts, liver and renal function, and pulmonary status. Common adverse effects include gastrointestinal disturbances, mucositis, hepatotoxicity, myelosuppression, and increased susceptibility to infections. Methotrexate is contraindicated in patients with severe renal or hepatic impairment, pregnancy, and active infections. Patients should be advised to avoid alcohol and live vaccines during treatment. Methora 15 Tablet should be administered under strict medical supervision with appropriate supportive measures to minimize adverse effects and optimize therapeutic outcomes.